ADVANCE-1: An adapted collaborative benchmarking approach in centre-based lung cancer care.

Benchmarking Guidelines Lung cancer Quality improvement Registry Service provision

Journal

Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805

Informations de publication

Date de publication:
01 2021
Historique:
received: 07 08 2020
revised: 04 11 2020
accepted: 15 11 2020
pubmed: 12 12 2020
medline: 28 5 2021
entrez: 11 12 2020
Statut: ppublish

Résumé

The majority of research within lung cancer is focused on prevention, diagnosis and treatment rather than examining infrastructure or processes of lung cancer centres. Benchmarking is a systematic method for documenting and comparing processes, functions or performance of organisations against the best in the world. ADVANCE-1 is a European Respiratory Society funded pilot study with the main aim of creating a benchmarking tool that can easily document and reflect the structure and process within a lung cancer centre and its associated registry. By doing this we can then compare centres and generate best practice learning points from each centre in order to learn from each other. The ADVANCE-1 study group was constituted by two ERS fellowship-holders and senior lung cancer specialists from the two participating lung cancer services in Glasgow, Scotland, and Berlin, Germany. The study design and benchmarking tools were reviewed externally. Once the benchmarking tools were created, prospective testing was undertaken in the two participating centres in order to allow comparison to ascertain best practice in a so called 'collaborative benchmarking approach'. We were then able to create personalised learning points for each centre. The next phase of the project will be to expand the benchmarking across several European centres in the ADANCE-2 project.

Identifiants

pubmed: 33307417
pii: S0169-5002(20)30694-2
doi: 10.1016/j.lungcan.2020.11.019
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

44-52

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Brendan McCann (B)

Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.

Riccardo Muhr (R)

Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany.

Noelle O'Rourke (N)

Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.

Robert Milroy (R)

Glasgow Royal Infirmary, Glasgow, United Kingdom.

Jens Kollmeier (J)

Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany.

Daniel Misch (D)

Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany.

Joris van der Horst (J)

Glasgow Royal Infirmary, Glasgow, United Kingdom.

David Morrison (D)

University of Glasgow, Glasgow, United Kingdom.

Torsten Bauer (T)

Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany.

Oliver Massalski (O)

German Benchmarking Centre, Berlin, Germany.

Torsten Gerriet Blum (TG)

Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany. Electronic address: torsten-gerriet.blum@helios-gesundheit.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH